Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies.
Adegoke NA, Gide TN, Mao Y, Quek C, Patrick E, Carlino MS, Lo SN, Menzies AM, Pires da Silva I, Vergara IA, Long G, Scolyer RA, Wilmott JS. Adegoke NA, et al. Among authors: gide tn. J Immunother Cancer. 2023 Oct;11(10):e007144. doi: 10.1136/jitc-2023-007144. J Immunother Cancer. 2023. PMID: 37865395 Free PMC article.
Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites.
Conway JW, Rawson RV, Lo S, Ahmed T, Vergara IA, Gide TN, Attrill GH, Carlino MS, Saw RPM, Thompson JF, Spillane AJ, Shannon KF, Shivalingam B, Menzies AM, Wilmott JS, Long GV, Scolyer RA, Pires da Silva I. Conway JW, et al. Among authors: gide tn. J Immunother Cancer. 2022 Sep;10(9):e004884. doi: 10.1136/jitc-2022-004884. J Immunother Cancer. 2022. PMID: 36096531 Free PMC article.
Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy.
Lee H, Ferguson AL, Quek C, Vergara IA, Pires daSilva I, Allen R, Gide TN, Conway JW, Koufariotis LT, Hayward NK, Waddell N, Carlino MS, Menzies AM, Saw RPM, Shklovskaya E, Rizos H, Lo S, Scolyer RA, Long GV, Palendira U, Wilmott JS. Lee H, et al. Among authors: gide tn. Clin Cancer Res. 2023 Jul 5;29(13):2513-2524. doi: 10.1158/1078-0432.CCR-22-2657. Clin Cancer Res. 2023. PMID: 36790412
Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach.
Mao Y, Gide TN, Adegoke NA, Quek C, Maher N, Potter A, Patrick E, Saw RPM, Thompson JF, Spillane AJ, Shannon KF, Carlino MS, Lo SN, Menzies AM, da Silva IP, Long GV, Scolyer RA, Wilmott JS. Mao Y, et al. Among authors: gide tn. J Transl Med. 2023 Apr 13;21(1):257. doi: 10.1186/s12967-023-04092-9. J Transl Med. 2023. PMID: 37055772 Free PMC article.
CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment.
Edwards J, Wilmott JS, Madore J, Gide TN, Quek C, Tasker A, Ferguson A, Chen J, Hewavisenti R, Hersey P, Gebhardt T, Weninger W, Britton WJ, Saw RPM, Thompson JF, Menzies AM, Long GV, Scolyer RA, Palendira U. Edwards J, et al. Among authors: gide tn. Clin Cancer Res. 2018 Jul 1;24(13):3036-3045. doi: 10.1158/1078-0432.CCR-17-2257. Epub 2018 Mar 29. Clin Cancer Res. 2018. PMID: 29599411
19 results